PLYMOUTH, Mass.--(BUSINESS WIRE)--Nov 2, 2023--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced preliminary clinical data from the dose escalation portion of the company蘑菇视频 ongoing Phase 1 ...
LONDON--(BUSINESS WIRE)--Nov 2, 2023--Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create novel cancer treatments, today announces that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application ...
JUPITER, Fla.--(BUSINESS WIRE)--Nov 2, 2023--<a ...
SAN DIEGO--(BUSINESS WIRE)--Nov 2, 2023--<a ...
GALWAY, Ireland--(BUSINESS WIRE)--Nov 2, 2023--<a ...
SCHLIEREN / ZURICH, Switzerland--(BUSINESS WIRE)--Nov 2, 2023--<a ...